Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Vasoconstrictor Agents | 20 | 2023 | 62 | 5.630 |
Why?
|
Shock | 12 | 2023 | 28 | 5.610 |
Why?
|
Respiratory Insufficiency | 8 | 2023 | 61 | 4.740 |
Why?
|
Hypotension | 12 | 2023 | 47 | 4.220 |
Why?
|
Angiotensin II | 13 | 2023 | 279 | 3.980 |
Why?
|
Postoperative Complications | 14 | 2023 | 670 | 3.860 |
Why?
|
Shock, Septic | 8 | 2023 | 28 | 3.640 |
Why?
|
Analgesics, Opioid | 10 | 2021 | 239 | 3.530 |
Why?
|
Critical Illness | 8 | 2024 | 87 | 3.180 |
Why?
|
Monitoring, Physiologic | 7 | 2022 | 68 | 3.160 |
Why?
|
Critical Care | 8 | 2023 | 114 | 2.480 |
Why?
|
Surgical Procedures, Operative | 8 | 2021 | 74 | 2.460 |
Why?
|
Heart Injuries | 4 | 2021 | 8 | 2.310 |
Why?
|
Humans | 95 | 2024 | 29123 | 2.160 |
Why?
|
Postoperative Care | 4 | 2020 | 72 | 2.150 |
Why?
|
Oximetry | 5 | 2021 | 28 | 1.960 |
Why?
|
Intensive Care Units | 10 | 2023 | 118 | 1.880 |
Why?
|
Norepinephrine | 7 | 2023 | 73 | 1.590 |
Why?
|
Capnography | 5 | 2022 | 9 | 1.550 |
Why?
|
Pain, Postoperative | 6 | 2020 | 174 | 1.520 |
Why?
|
Physical Examination | 2 | 2023 | 82 | 1.520 |
Why?
|
Hemodynamics | 5 | 2021 | 148 | 1.500 |
Why?
|
Blood Pressure | 7 | 2023 | 806 | 1.420 |
Why?
|
Adrenergic beta-Antagonists | 2 | 2020 | 59 | 1.420 |
Why?
|
Coronavirus Infections | 2 | 2020 | 72 | 1.350 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 77 | 1.350 |
Why?
|
Monitoring, Intraoperative | 5 | 2021 | 39 | 1.250 |
Why?
|
Atrial Fibrillation | 4 | 2020 | 314 | 1.230 |
Why?
|
Anesthesiology | 3 | 2022 | 49 | 1.120 |
Why?
|
Myocardial Ischemia | 3 | 2021 | 83 | 1.110 |
Why?
|
Middle Aged | 33 | 2021 | 10834 | 1.060 |
Why?
|
Anesthesia | 3 | 2022 | 65 | 1.040 |
Why?
|
Sepsis | 3 | 2024 | 147 | 1.020 |
Why?
|
Resuscitation | 2 | 2023 | 56 | 0.980 |
Why?
|
Aged | 23 | 2023 | 9492 | 0.970 |
Why?
|
Male | 42 | 2022 | 17815 | 0.960 |
Why?
|
Female | 36 | 2023 | 18173 | 0.920 |
Why?
|
Analgesia, Patient-Controlled | 3 | 2020 | 19 | 0.920 |
Why?
|
Goals | 1 | 2023 | 36 | 0.920 |
Why?
|
Hypovolemia | 1 | 2023 | 3 | 0.910 |
Why?
|
Prospective Studies | 12 | 2023 | 2021 | 0.900 |
Why?
|
Sleep Apnea, Obstructive | 3 | 2022 | 47 | 0.890 |
Why?
|
Retrospective Studies | 14 | 2023 | 3112 | 0.860 |
Why?
|
Risk Assessment | 9 | 2021 | 1306 | 0.830 |
Why?
|
Adult | 27 | 2022 | 8426 | 0.820 |
Why?
|
Vasodilation | 2 | 2019 | 87 | 0.810 |
Why?
|
Microcirculation | 1 | 2021 | 61 | 0.780 |
Why?
|
Anesthesia Department, Hospital | 1 | 2020 | 1 | 0.770 |
Why?
|
Respiratory Rate | 4 | 2022 | 12 | 0.760 |
Why?
|
Spiro Compounds | 1 | 2020 | 8 | 0.760 |
Why?
|
Thiophenes | 1 | 2020 | 21 | 0.750 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2020 | 29 | 0.740 |
Why?
|
Morphine | 1 | 2020 | 57 | 0.740 |
Why?
|
Treatment Outcome | 11 | 2021 | 3101 | 0.720 |
Why?
|
Vital Signs | 1 | 2019 | 7 | 0.710 |
Why?
|
Patients' Rooms | 1 | 2019 | 4 | 0.700 |
Why?
|
Lactic Acid | 1 | 2019 | 52 | 0.670 |
Why?
|
Carbon Dioxide | 2 | 2018 | 36 | 0.660 |
Why?
|
Health Services Needs and Demand | 1 | 2019 | 66 | 0.660 |
Why?
|
Renin-Angiotensin System | 1 | 2020 | 182 | 0.660 |
Why?
|
Emergency Medical Services | 1 | 2020 | 157 | 0.650 |
Why?
|
Hospitalization | 3 | 2022 | 417 | 0.640 |
Why?
|
Risk Factors | 13 | 2021 | 3537 | 0.630 |
Why?
|
Intubation, Intratracheal | 3 | 2021 | 70 | 0.620 |
Why?
|
Vasopressins | 4 | 2023 | 17 | 0.610 |
Why?
|
Aged, 80 and over | 9 | 2021 | 3719 | 0.600 |
Why?
|
Respiration, Artificial | 3 | 2023 | 96 | 0.590 |
Why?
|
Health Services Accessibility | 1 | 2019 | 231 | 0.580 |
Why?
|
Catecholamines | 4 | 2020 | 17 | 0.570 |
Why?
|
Inpatients | 3 | 2021 | 64 | 0.560 |
Why?
|
Analgesia, Epidural | 1 | 2016 | 50 | 0.560 |
Why?
|
Anesthetics, Local | 1 | 2016 | 77 | 0.560 |
Why?
|
Cohort Studies | 7 | 2023 | 1688 | 0.550 |
Why?
|
Arthroplasty, Replacement, Knee | 1 | 2016 | 84 | 0.530 |
Why?
|
Pulmonary Veins | 1 | 2014 | 9 | 0.510 |
Why?
|
Vascular Malformations | 1 | 2014 | 8 | 0.510 |
Why?
|
Incidence | 5 | 2020 | 1119 | 0.500 |
Why?
|
Hospital Mortality | 6 | 2022 | 186 | 0.490 |
Why?
|
Catheterization, Central Venous | 1 | 2014 | 60 | 0.480 |
Why?
|
Anti-Infective Agents | 2 | 2017 | 43 | 0.450 |
Why?
|
Surgical Wound Infection | 2 | 2017 | 74 | 0.420 |
Why?
|
Intraoperative Complications | 2 | 2023 | 49 | 0.400 |
Why?
|
Infectious Disease Transmission, Patient-to-Professional | 1 | 2021 | 11 | 0.400 |
Why?
|
Academic Medical Centers | 2 | 2023 | 150 | 0.380 |
Why?
|
Scopolamine | 3 | 2016 | 6 | 0.370 |
Why?
|
Cardiac Surgical Procedures | 2 | 2021 | 71 | 0.370 |
Why?
|
Blood Pressure Determination | 3 | 2020 | 94 | 0.370 |
Why?
|
Double-Blind Method | 5 | 2019 | 503 | 0.360 |
Why?
|
Propensity Score | 2 | 2020 | 34 | 0.360 |
Why?
|
Depressive Disorder, Major | 3 | 2016 | 36 | 0.360 |
Why?
|
Postoperative Period | 2 | 2020 | 91 | 0.350 |
Why?
|
Heart Arrest | 2 | 2019 | 39 | 0.340 |
Why?
|
Renin | 2 | 2020 | 112 | 0.340 |
Why?
|
Physicians | 1 | 2021 | 134 | 0.340 |
Why?
|
Ureteral Obstruction | 2 | 2018 | 29 | 0.330 |
Why?
|
Time Factors | 8 | 2021 | 2001 | 0.310 |
Why?
|
Antibiotic Prophylaxis | 1 | 2017 | 29 | 0.310 |
Why?
|
Preoperative Care | 2 | 2020 | 110 | 0.310 |
Why?
|
Pain Measurement | 2 | 2020 | 364 | 0.300 |
Why?
|
Prognosis | 4 | 2020 | 1362 | 0.300 |
Why?
|
Bariatric Surgery | 3 | 2015 | 16 | 0.290 |
Why?
|
Oxygen | 3 | 2016 | 139 | 0.290 |
Why?
|
United States | 6 | 2023 | 3632 | 0.280 |
Why?
|
Pulmonary Alveolar Proteinosis | 2 | 2016 | 2 | 0.280 |
Why?
|
Bronchoalveolar Lavage | 2 | 2016 | 15 | 0.270 |
Why?
|
Lung Diseases, Interstitial | 2 | 2016 | 9 | 0.270 |
Why?
|
Aspirin | 2 | 2022 | 62 | 0.250 |
Why?
|
Electronics | 1 | 2023 | 14 | 0.240 |
Why?
|
Nitroglycerin | 1 | 2003 | 11 | 0.240 |
Why?
|
Intestinal Diseases | 1 | 2003 | 18 | 0.240 |
Why?
|
Vasodilator Agents | 1 | 2003 | 54 | 0.230 |
Why?
|
Oxygen Inhalation Therapy | 1 | 2023 | 8 | 0.230 |
Why?
|
Databases, Factual | 2 | 2022 | 332 | 0.230 |
Why?
|
Tomography, X-Ray Computed | 3 | 2018 | 871 | 0.230 |
Why?
|
Peptide Hormones | 1 | 2023 | 11 | 0.230 |
Why?
|
Reperfusion Injury | 1 | 2003 | 43 | 0.220 |
Why?
|
Drug Therapy, Combination | 3 | 2019 | 273 | 0.220 |
Why?
|
Aftercare | 1 | 2022 | 28 | 0.220 |
Why?
|
Virus Diseases | 1 | 2022 | 19 | 0.220 |
Why?
|
Antidepressive Agents | 2 | 2015 | 70 | 0.220 |
Why?
|
Patient Readmission | 2 | 2021 | 105 | 0.220 |
Why?
|
Medicare | 1 | 2023 | 186 | 0.210 |
Why?
|
Europe | 2 | 2018 | 77 | 0.210 |
Why?
|
Data Collection | 1 | 2022 | 163 | 0.210 |
Why?
|
Propofol | 2 | 2012 | 19 | 0.200 |
Why?
|
Predictive Value of Tests | 2 | 2020 | 787 | 0.200 |
Why?
|
Motivation | 1 | 2022 | 102 | 0.200 |
Why?
|
Lung Transplantation | 1 | 2021 | 6 | 0.200 |
Why?
|
Endarterectomy | 1 | 2021 | 7 | 0.200 |
Why?
|
Delphi Technique | 1 | 2021 | 35 | 0.200 |
Why?
|
Thoracic Surgical Procedures | 1 | 2021 | 12 | 0.200 |
Why?
|
Consensus | 1 | 2021 | 68 | 0.200 |
Why?
|
Echocardiography, Transesophageal | 1 | 2021 | 40 | 0.190 |
Why?
|
Vasoplegia | 1 | 2020 | 1 | 0.190 |
Why?
|
Patient Admission | 1 | 2021 | 53 | 0.190 |
Why?
|
APACHE | 1 | 2020 | 12 | 0.190 |
Why?
|
Job Satisfaction | 1 | 2021 | 37 | 0.190 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2021 | 82 | 0.190 |
Why?
|
Fibrinolytic Agents | 1 | 2021 | 70 | 0.190 |
Why?
|
Practice Guidelines as Topic | 2 | 2020 | 374 | 0.190 |
Why?
|
Systemic Inflammatory Response Syndrome | 1 | 2020 | 11 | 0.190 |
Why?
|
International Classification of Diseases | 1 | 2020 | 26 | 0.190 |
Why?
|
Terminology as Topic | 1 | 2020 | 62 | 0.180 |
Why?
|
Delirium | 1 | 2020 | 13 | 0.180 |
Why?
|
Decision Making | 1 | 2022 | 180 | 0.180 |
Why?
|
Comorbidity | 2 | 2019 | 540 | 0.180 |
Why?
|
Cross Infection | 1 | 2020 | 46 | 0.180 |
Why?
|
Myocardial Infarction | 2 | 2021 | 413 | 0.180 |
Why?
|
Models, Theoretical | 1 | 2020 | 126 | 0.180 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 134 | 0.180 |
Why?
|
Delayed Diagnosis | 1 | 2019 | 12 | 0.170 |
Why?
|
Artificial Intelligence | 1 | 2019 | 49 | 0.170 |
Why?
|
Patients | 1 | 2019 | 46 | 0.170 |
Why?
|
Cardiac Output | 1 | 2018 | 32 | 0.170 |
Why?
|
Kidney Pelvis | 1 | 2018 | 21 | 0.170 |
Why?
|
Sensitivity and Specificity | 1 | 2020 | 532 | 0.170 |
Why?
|
Kidney Calculi | 1 | 2018 | 25 | 0.170 |
Why?
|
Multicystic Dysplastic Kidney | 1 | 2018 | 1 | 0.170 |
Why?
|
Cystostomy | 1 | 2018 | 3 | 0.160 |
Why?
|
Hydronephrosis | 1 | 2018 | 12 | 0.160 |
Why?
|
Hematuria | 1 | 2018 | 7 | 0.160 |
Why?
|
Polysomnography | 2 | 2015 | 33 | 0.160 |
Why?
|
Hypertension, Portal | 1 | 2018 | 9 | 0.160 |
Why?
|
Varicose Veins | 1 | 2018 | 6 | 0.160 |
Why?
|
Severity of Illness Index | 2 | 2019 | 863 | 0.160 |
Why?
|
Analgesia | 1 | 2018 | 33 | 0.160 |
Why?
|
Multicenter Studies as Topic | 1 | 2018 | 92 | 0.160 |
Why?
|
Urologic Surgical Procedures | 1 | 2018 | 60 | 0.160 |
Why?
|
Equipment Design | 1 | 2018 | 167 | 0.160 |
Why?
|
Angiotensin I | 1 | 2020 | 262 | 0.160 |
Why?
|
Body Mass Index | 1 | 2021 | 865 | 0.160 |
Why?
|
Longitudinal Studies | 1 | 2020 | 721 | 0.160 |
Why?
|
Hospitals | 1 | 2018 | 89 | 0.160 |
Why?
|
Surgical Flaps | 1 | 2018 | 69 | 0.160 |
Why?
|
Hypoglycemic Agents | 3 | 2009 | 176 | 0.160 |
Why?
|
Length of Stay | 1 | 2018 | 292 | 0.150 |
Why?
|
Embolization, Therapeutic | 1 | 2018 | 79 | 0.150 |
Why?
|
Algorithms | 1 | 2020 | 462 | 0.150 |
Why?
|
Proportional Hazards Models | 1 | 2019 | 709 | 0.150 |
Why?
|
Myocardium | 1 | 2018 | 170 | 0.150 |
Why?
|
Physical Therapy Modalities | 1 | 2017 | 60 | 0.150 |
Why?
|
Patient Acceptance of Health Care | 1 | 2019 | 154 | 0.150 |
Why?
|
Amides | 1 | 2016 | 20 | 0.150 |
Why?
|
Fentanyl | 1 | 2016 | 33 | 0.150 |
Why?
|
Nausea | 1 | 2016 | 49 | 0.150 |
Why?
|
Drug Combinations | 1 | 2016 | 86 | 0.150 |
Why?
|
Early Detection of Cancer | 1 | 2017 | 73 | 0.150 |
Why?
|
Facial Expression | 1 | 2016 | 3 | 0.140 |
Why?
|
Emergency Service, Hospital | 1 | 2020 | 430 | 0.140 |
Why?
|
Cardiomyopathy, Hypertrophic | 1 | 2016 | 3 | 0.140 |
Why?
|
Bupivacaine | 1 | 2016 | 48 | 0.140 |
Why?
|
Muscarinic Antagonists | 1 | 2016 | 15 | 0.140 |
Why?
|
Heart Rate | 1 | 2018 | 315 | 0.140 |
Why?
|
Urinary Bladder | 1 | 2018 | 165 | 0.140 |
Why?
|
Laparoscopy | 2 | 2015 | 169 | 0.140 |
Why?
|
Osteoarthritis | 1 | 2016 | 74 | 0.140 |
Why?
|
Amygdala | 1 | 2016 | 60 | 0.140 |
Why?
|
Patient Simulation | 1 | 2015 | 30 | 0.130 |
Why?
|
Problem-Based Learning | 1 | 2015 | 26 | 0.130 |
Why?
|
Glycopeptides | 1 | 2015 | 3 | 0.130 |
Why?
|
beta-Lactams | 1 | 2015 | 5 | 0.130 |
Why?
|
Sleep Apnea Syndromes | 1 | 2015 | 28 | 0.130 |
Why?
|
Cardiovascular Surgical Procedures | 1 | 2015 | 5 | 0.130 |
Why?
|
Anesthetics, Intravenous | 2 | 2012 | 17 | 0.130 |
Why?
|
Patient Satisfaction | 1 | 2016 | 222 | 0.130 |
Why?
|
Blood Gas Analysis | 1 | 2014 | 16 | 0.130 |
Why?
|
Incidental Findings | 1 | 2014 | 26 | 0.130 |
Why?
|
Vitamin D Deficiency | 1 | 2015 | 89 | 0.120 |
Why?
|
Orthopedic Procedures | 1 | 2015 | 92 | 0.120 |
Why?
|
Lung Neoplasms | 1 | 2017 | 384 | 0.120 |
Why?
|
Vitamin D | 1 | 2015 | 172 | 0.120 |
Why?
|
Ohio | 3 | 2020 | 54 | 0.110 |
Why?
|
Drug Resistance, Microbial | 2 | 2017 | 11 | 0.110 |
Why?
|
Conscious Sedation | 1 | 2012 | 24 | 0.100 |
Why?
|
Hypnotics and Sedatives | 1 | 2012 | 27 | 0.100 |
Why?
|
Internship and Residency | 1 | 2015 | 283 | 0.100 |
Why?
|
Anti-Bacterial Agents | 2 | 2020 | 285 | 0.100 |
Why?
|
Kidney | 1 | 2016 | 486 | 0.100 |
Why?
|
Electroconvulsive Therapy | 1 | 2011 | 25 | 0.100 |
Why?
|
Cross-Sectional Studies | 3 | 2021 | 1362 | 0.100 |
Why?
|
Electroencephalography | 1 | 2011 | 71 | 0.100 |
Why?
|
Seizures | 1 | 2011 | 61 | 0.100 |
Why?
|
Anti-Anxiety Agents | 1 | 2010 | 13 | 0.100 |
Why?
|
Bipolar Disorder | 1 | 2010 | 15 | 0.100 |
Why?
|
Patient Discharge | 2 | 2022 | 168 | 0.090 |
Why?
|
Receptors, Glucagon | 1 | 2009 | 2 | 0.090 |
Why?
|
Oligopeptides | 1 | 2009 | 51 | 0.090 |
Why?
|
Dipeptides | 2 | 2005 | 9 | 0.080 |
Why?
|
Encephalocele | 1 | 2007 | 2 | 0.080 |
Why?
|
Proline | 2 | 2005 | 10 | 0.080 |
Why?
|
Brain | 1 | 2015 | 930 | 0.080 |
Why?
|
Nitriles | 2 | 2005 | 22 | 0.080 |
Why?
|
Antifungal Agents | 1 | 2017 | 33 | 0.080 |
Why?
|
Intubation, Gastrointestinal | 1 | 2007 | 12 | 0.080 |
Why?
|
Anesthesia, Inhalation | 1 | 2007 | 16 | 0.080 |
Why?
|
Prevalence | 2 | 2020 | 898 | 0.080 |
Why?
|
Obesity | 1 | 2015 | 1063 | 0.080 |
Why?
|
Adamantane | 1 | 2005 | 3 | 0.070 |
Why?
|
Clinical Competence | 2 | 2021 | 307 | 0.070 |
Why?
|
Protease Inhibitors | 1 | 2005 | 14 | 0.070 |
Why?
|
Glycine | 1 | 2005 | 25 | 0.070 |
Why?
|
Rats | 3 | 2005 | 1604 | 0.070 |
Why?
|
Animals | 6 | 2012 | 7300 | 0.070 |
Why?
|
Adolescent | 4 | 2018 | 3255 | 0.070 |
Why?
|
Cross-Over Studies | 2 | 2015 | 94 | 0.070 |
Why?
|
Linear Models | 2 | 2016 | 426 | 0.060 |
Why?
|
Multivariate Analysis | 2 | 2016 | 637 | 0.060 |
Why?
|
Regression Analysis | 2 | 2015 | 274 | 0.060 |
Why?
|
Cyclopropanes | 1 | 2004 | 19 | 0.060 |
Why?
|
Neutrophil Activation | 1 | 2003 | 5 | 0.060 |
Why?
|
Bile | 1 | 2003 | 6 | 0.060 |
Why?
|
Permeability | 1 | 2003 | 9 | 0.060 |
Why?
|
Neutrophil Infiltration | 1 | 2003 | 9 | 0.060 |
Why?
|
Platelet Activating Factor | 1 | 2003 | 14 | 0.060 |
Why?
|
Receptors, Corticotropin | 1 | 2003 | 2 | 0.060 |
Why?
|
Intestines | 1 | 2003 | 54 | 0.060 |
Why?
|
Enzyme Inhibitors | 1 | 2004 | 162 | 0.060 |
Why?
|
Tyrosine | 1 | 2003 | 22 | 0.060 |
Why?
|
Shock, Cardiogenic | 1 | 2023 | 7 | 0.060 |
Why?
|
Intestinal Mucosa | 1 | 2003 | 64 | 0.060 |
Why?
|
Administration, Topical | 1 | 2003 | 130 | 0.060 |
Why?
|
Models, Animal | 1 | 2003 | 160 | 0.060 |
Why?
|
Nitric Oxide | 1 | 2003 | 116 | 0.060 |
Why?
|
Reactive Oxygen Species | 1 | 2003 | 159 | 0.050 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2003 | 71 | 0.050 |
Why?
|
Specialty Boards | 1 | 2021 | 9 | 0.050 |
Why?
|
Rats, Sprague-Dawley | 1 | 2003 | 747 | 0.050 |
Why?
|
Research Design | 1 | 2022 | 286 | 0.050 |
Why?
|
Workplace | 1 | 2021 | 47 | 0.050 |
Why?
|
Middle East | 1 | 2020 | 5 | 0.050 |
Why?
|
Asia | 1 | 2020 | 17 | 0.050 |
Why?
|
Burnout, Professional | 1 | 2021 | 44 | 0.050 |
Why?
|
Cardiopulmonary Bypass | 1 | 2020 | 57 | 0.050 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2020 | 57 | 0.050 |
Why?
|
Health Care Surveys | 1 | 2021 | 176 | 0.050 |
Why?
|
Troponin | 1 | 2020 | 79 | 0.050 |
Why?
|
Quality-Adjusted Life Years | 1 | 2019 | 23 | 0.050 |
Why?
|
Magnetic Resonance Imaging | 2 | 2016 | 1219 | 0.050 |
Why?
|
Registries | 1 | 2021 | 278 | 0.040 |
Why?
|
Early Diagnosis | 1 | 2019 | 61 | 0.040 |
Why?
|
Pilot Projects | 1 | 2021 | 469 | 0.040 |
Why?
|
Attitude of Health Personnel | 1 | 2021 | 162 | 0.040 |
Why?
|
Cost-Benefit Analysis | 1 | 2019 | 159 | 0.040 |
Why?
|
Neurophysins | 1 | 2018 | 1 | 0.040 |
Why?
|
Protein Precursors | 1 | 2018 | 22 | 0.040 |
Why?
|
Canada | 1 | 2018 | 49 | 0.040 |
Why?
|
Australia | 1 | 2018 | 66 | 0.040 |
Why?
|
Young Adult | 2 | 2018 | 2402 | 0.040 |
Why?
|
Albumins | 1 | 2018 | 38 | 0.040 |
Why?
|
Enbucrilate | 1 | 2018 | 1 | 0.040 |
Why?
|
Liver Cirrhosis, Alcoholic | 1 | 2018 | 2 | 0.040 |
Why?
|
Tissue Adhesives | 1 | 2018 | 5 | 0.040 |
Why?
|
Models, Biological | 1 | 2020 | 373 | 0.040 |
Why?
|
Morbidity | 1 | 2018 | 91 | 0.040 |
Why?
|
Chi-Square Distribution | 1 | 2018 | 293 | 0.040 |
Why?
|
Heart | 1 | 2019 | 162 | 0.040 |
Why?
|
Blood Transfusion | 1 | 2018 | 64 | 0.040 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2021 | 326 | 0.040 |
Why?
|
Injections, Intravenous | 1 | 2017 | 73 | 0.040 |
Why?
|
Feasibility Studies | 1 | 2018 | 263 | 0.040 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2019 | 464 | 0.040 |
Why?
|
Oxyhemoglobins | 1 | 2016 | 6 | 0.040 |
Why?
|
Least-Squares Analysis | 1 | 2016 | 29 | 0.040 |
Why?
|
Odds Ratio | 1 | 2018 | 447 | 0.040 |
Why?
|
Models, Molecular | 2 | 2009 | 178 | 0.040 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2005 | 1379 | 0.040 |
Why?
|
Survival Analysis | 1 | 2017 | 440 | 0.040 |
Why?
|
Mice | 3 | 2009 | 2371 | 0.030 |
Why?
|
Warm Ischemia | 1 | 2016 | 8 | 0.030 |
Why?
|
Kidney Function Tests | 1 | 2016 | 102 | 0.030 |
Why?
|
Mass Screening | 1 | 2017 | 223 | 0.030 |
Why?
|
Creatinine | 1 | 2016 | 174 | 0.030 |
Why?
|
Operating Rooms | 1 | 2015 | 32 | 0.030 |
Why?
|
Rats, Zucker | 2 | 2005 | 5 | 0.030 |
Why?
|
Enterococcus | 1 | 2015 | 10 | 0.030 |
Why?
|
Causality | 1 | 2015 | 37 | 0.030 |
Why?
|
Intraoperative Period | 1 | 2015 | 37 | 0.030 |
Why?
|
Educational Measurement | 1 | 2015 | 111 | 0.030 |
Why?
|
Antihypertensive Agents | 1 | 2018 | 342 | 0.030 |
Why?
|
Emotions | 1 | 2015 | 48 | 0.030 |
Why?
|
Glomerular Filtration Rate | 1 | 2016 | 287 | 0.030 |
Why?
|
Methicillin-Resistant Staphylococcus aureus | 1 | 2015 | 24 | 0.030 |
Why?
|
Nephrectomy | 1 | 2016 | 114 | 0.030 |
Why?
|
Cerebrovascular Circulation | 1 | 2015 | 95 | 0.030 |
Why?
|
Attention | 1 | 2015 | 83 | 0.030 |
Why?
|
Photic Stimulation | 1 | 2015 | 155 | 0.030 |
Why?
|
Obesity, Morbid | 1 | 2015 | 55 | 0.030 |
Why?
|
Structure-Activity Relationship | 2 | 2005 | 82 | 0.030 |
Why?
|
Brain Mapping | 1 | 2015 | 182 | 0.030 |
Why?
|
Logistic Models | 1 | 2016 | 727 | 0.030 |
Why?
|
Case-Control Studies | 1 | 2016 | 859 | 0.030 |
Why?
|
Models, Statistical | 1 | 2015 | 163 | 0.030 |
Why?
|
Neuropsychological Tests | 1 | 2015 | 379 | 0.030 |
Why?
|
Chronic Disease | 1 | 2015 | 370 | 0.030 |
Why?
|
Drug Dosage Calculations | 1 | 2012 | 7 | 0.030 |
Why?
|
Safety | 1 | 2011 | 72 | 0.020 |
Why?
|
Stroke | 1 | 2016 | 548 | 0.020 |
Why?
|
Placebos | 1 | 2010 | 61 | 0.020 |
Why?
|
Heart Failure | 1 | 2016 | 571 | 0.020 |
Why?
|
Psychiatric Status Rating Scales | 1 | 2010 | 92 | 0.020 |
Why?
|
Mental Disorders | 1 | 2011 | 103 | 0.020 |
Why?
|
Single-Blind Method | 1 | 2010 | 165 | 0.020 |
Why?
|
Patient Selection | 1 | 2012 | 257 | 0.020 |
Why?
|
Cricetulus | 1 | 2009 | 17 | 0.020 |
Why?
|
CHO Cells | 1 | 2009 | 25 | 0.020 |
Why?
|
Cricetinae | 1 | 2009 | 58 | 0.020 |
Why?
|
Follow-Up Studies | 1 | 2015 | 2109 | 0.020 |
Why?
|
Protein Conformation | 1 | 2009 | 85 | 0.020 |
Why?
|
Dogs | 1 | 2009 | 117 | 0.020 |
Why?
|
Sex Characteristics | 1 | 2010 | 167 | 0.020 |
Why?
|
Amino Acid Sequence | 1 | 2009 | 280 | 0.020 |
Why?
|
Molecular Sequence Data | 1 | 2009 | 350 | 0.020 |
Why?
|
Hypertension | 1 | 2016 | 910 | 0.020 |
Why?
|
Occipital Lobe | 1 | 2007 | 7 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2009 | 641 | 0.020 |
Why?
|
Sodium Hydroxide | 1 | 2007 | 2 | 0.020 |
Why?
|
Corrosion | 1 | 2007 | 2 | 0.020 |
Why?
|
Arytenoid Cartilage | 1 | 2007 | 2 | 0.020 |
Why?
|
Calcium Compounds | 1 | 2007 | 8 | 0.020 |
Why?
|
Oropharynx | 1 | 2007 | 7 | 0.020 |
Why?
|
Fiber Optic Technology | 1 | 2007 | 14 | 0.020 |
Why?
|
Oxides | 1 | 2007 | 15 | 0.020 |
Why?
|
Anesthetics, Inhalation | 1 | 2007 | 17 | 0.020 |
Why?
|
Equipment Failure | 1 | 2007 | 22 | 0.020 |
Why?
|
Laryngoscopy | 1 | 2007 | 39 | 0.020 |
Why?
|
Bronchoscopy | 1 | 2007 | 56 | 0.020 |
Why?
|
Microsomes, Liver | 1 | 2005 | 11 | 0.020 |
Why?
|
Stereoisomerism | 1 | 2005 | 21 | 0.020 |
Why?
|
Biological Availability | 1 | 2005 | 21 | 0.020 |
Why?
|
Mice, Obese | 1 | 2005 | 22 | 0.020 |
Why?
|
Infant, Newborn | 1 | 2007 | 599 | 0.020 |
Why?
|
Glucose Tolerance Test | 1 | 2005 | 125 | 0.020 |
Why?
|
Drug Stability | 1 | 2004 | 8 | 0.020 |
Why?
|
Molecular Conformation | 1 | 2004 | 8 | 0.020 |
Why?
|
Molecular Mimicry | 1 | 2004 | 2 | 0.020 |
Why?
|
Solutions | 1 | 2004 | 26 | 0.020 |
Why?
|
Crystallography, X-Ray | 1 | 2004 | 77 | 0.020 |
Why?
|
Receptors, Melanocortin | 1 | 2003 | 1 | 0.010 |
Why?
|
Combinatorial Chemistry Techniques | 1 | 2003 | 3 | 0.010 |
Why?
|
Insulin | 1 | 2005 | 346 | 0.010 |
Why?
|
Computer Simulation | 1 | 2004 | 207 | 0.010 |
Why?
|
Tumor Cells, Cultured | 1 | 2003 | 158 | 0.010 |
Why?
|
Mice, Inbred BALB C | 1 | 2003 | 160 | 0.010 |
Why?
|
Lipopolysaccharides | 1 | 2003 | 107 | 0.010 |
Why?
|
Blood Glucose | 1 | 2005 | 466 | 0.010 |
Why?
|
Acute Disease | 1 | 2003 | 239 | 0.010 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2003 | 200 | 0.010 |
Why?
|
Inflammation | 1 | 2003 | 508 | 0.010 |
Why?
|